NiceCupOfTea said...
Why would this work where Remicade and Humira failed to work, and I don't mean initially worked and then stopped working, I mean never worked?
It has a different mechanism of action. If your IBD is not driven by TNFalpha, a TNF inhibitor is not going to work for you.
Therapies that target leucocyte trafficking (anti-integrins) have also been developed and are associated with good clinical response in CD. Natalizumab (anti-α4 integrin antibody) is associated with important side effects and is not used anymore in gastroenterology in Europe but is still used in the USA. Vedolizumab (MLN0002), an anti-α4β7 integrin antibody, has a good efficacy and safety profile. Monoclonal antibodies targeting other cytokines are also under development. For example, ustekinumab (CNTO 1275) inhibits interleukins 12 and 23. It is associated with a good clinical response in CD.